Literature DB >> 35511145

Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype.

Megan A Clarke1, Susan S Devesa1, Anne Hammer2,3, Nicolas Wentzensen1.   

Abstract

Importance: Uterine cancer incidence has been increasing, particularly rates of aggressive, nonendometrioid subtypes, which are disproportionately higher among non-Hispanic Black women. The association of subtype-specific trends with uterine cancer mortality and with the role of tumor subtype and stage at diagnosis with racial disparities in uterine cancer deaths at the population-based level are not known. Objective: To estimate histologic subtype- and stage-specific uterine cancer mortality rates by race and ethnicity, corrected for hysterectomy. Design, Setting, and Participants: This cohort study used the US Surveillance, Epidemiology, and End Results-18 Incidence-Based Mortality database, representing approximately 26% of the US population and including deaths that occurred from 2000 to 2017. Hysterectomy correction was based on hysterectomy prevalence data from the Behavioral Risk Factor Surveillance System. Uncorrected and corrected rates associated with uterine corpus cancer cases diagnosed between 2000 and 2017 and uterine corpus cancer deaths occurring between 2010 and 2017 were age-adjusted to the 2000 US standard population and are expressed per 100 000 person-years, and annual percent changes in rates were calculated using log-linear regression. Data analysis was performed from March 10 to May 20, 2021. Exposures: Tumor histologic subtype, cancer stage at diagnosis, and race and ethnicity.
Results: Among 208 587 women diagnosed with uterine cancer during 2000-2017 (15 983 [7.7%] were Asian; 20 302 [9.7%] Black; 23 096 [11.1%] Hispanic; and 149 206 [71.5%] White individuals), there were 16 797 uterine cancer deaths between 2010 and 2017, corresponding to a hysterectomy-corrected mortality rate of 15.7 per 100 000 person-years. Hysterectomy-corrected rates were highest among Black women, overall, by histologic subtype and stage at diagnosis. Among all women, uterine corpus cancer mortality rates increased significantly by 1.8% (95% CI, 1.5%-2.9%) per year from 2010 to 2017, as did rates of nonendometrioid carcinomas (2.7%; 95% CI, 1.8%-3.6%), with increases occurring in Asian (3.4%; 95% CI, 0.3%-6.6%), Black (3.5%; 95% CI, 2.2%-4.9%), Hispanic (6.7%; 95% CI, 1.9%-11.8%), and White women (1.5%; 95% CI, 0.6%-2.4%). In contrast, endometrioid carcinoma mortality rates remained stable. Conclusions and Relevance: The findings of this cohort study suggest a significant increase of nonendometrioid uterine carcinoma mortality rates, aligning with recent incidence trends. The factors associated with these trends are not well understood and require more investigation of possible mechanisms. Despite stable incidence rates, endometrioid cancer mortality rates have not decreased over the past decade at the population level, suggesting limited progress in treatment for these cancers. The substantial disparities in uterine corpus cancer mortality rates among non-Hispanic Black women cannot be fully explained by subtype distribution and stage at diagnosis.

Entities:  

Mesh:

Year:  2022        PMID: 35511145      PMCID: PMC9073658          DOI: 10.1001/jamaoncol.2022.0009

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   33.006


  31 in total

Review 1.  Endometrial Cancer.

Authors:  Karen H Lu; Russell R Broaddus
Journal:  N Engl J Med       Date:  2020-11-19       Impact factor: 91.245

2.  Trends in hysterectomy-corrected uterine cancer mortality rates during 2002 to 2015: mortality of nonendometrioid cancer on the rise?

Authors:  Line W Gustafson; Berit B Booth; Johnny Kahlert; Gitte Ørtoft; Else Mejlgaard; Megan A Clarke; Nicolas Wentzensen; Anne F Rositch; Anne Hammer
Journal:  Int J Cancer       Date:  2020-08-17       Impact factor: 7.396

3.  Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.

Authors:  Alicia Leon-Castillo; Nanda Horeweg; Elke E M Peters; Tessa Rutten; Natalja Ter Haar; Vincent T H B M Smit; Cor D Kroon; Marie Boennelycke; Estrid Hogdall; Claus Hogdall; Remi R A Nout; Carien L Creutzberg; Gitte Ortoft; Tjalling Bosse
Journal:  Gynecol Oncol       Date:  2022-01-23       Impact factor: 5.482

4.  The impact of race on outcomes of patients with early stage uterine endometrioid carcinoma.

Authors:  Mohamed A Elshaikh; Adnan R Munkarah; Jared R Robbins; Benjamin S Laser; Neil Bhatt; Chad Cogan; Farzan Siddiqui
Journal:  Gynecol Oncol       Date:  2012-10-23       Impact factor: 5.482

5.  Comorbidities and endometrial cancer survival in Hispanics and non-Hispanic whites.

Authors:  Linda S Cook; Harold E Nelson; Myles Cockburn; Sara H Olson; Carolyn Y Muller; Charles L Wiggins
Journal:  Cancer Causes Control       Date:  2012-10-30       Impact factor: 2.506

Review 6.  Type I and II endometrial cancers: have they different risk factors?

Authors:  Veronica Wendy Setiawan; Hannah P Yang; Malcolm C Pike; Susan E McCann; Herbert Yu; Yong-Bing Xiang; Alicja Wolk; Nicolas Wentzensen; Noel S Weiss; Penelope M Webb; Piet A van den Brandt; Koen van de Vijver; Pamela J Thompson; Brian L Strom; Amanda B Spurdle; Robert A Soslow; Xiao-ou Shu; Catherine Schairer; Carlotta Sacerdote; Thomas E Rohan; Kim Robien; Harvey A Risch; Fulvio Ricceri; Timothy R Rebbeck; Radhai Rastogi; Jennifer Prescott; Silvia Polidoro; Yikyung Park; Sara H Olson; Kirsten B Moysich; Anthony B Miller; Marjorie L McCullough; Rayna K Matsuno; Anthony M Magliocco; Galina Lurie; Lingeng Lu; Jolanta Lissowska; Xiaolin Liang; James V Lacey; Laurence N Kolonel; Brian E Henderson; Susan E Hankinson; Niclas Håkansson; Marc T Goodman; Mia M Gaudet; Montserrat Garcia-Closas; Christine M Friedenreich; Jo L Freudenheim; Jennifer Doherty; Immaculata De Vivo; Kerry S Courneya; Linda S Cook; Chu Chen; James R Cerhan; Hui Cai; Louise A Brinton; Leslie Bernstein; Kristin E Anderson; Hoda Anton-Culver; Leo J Schouten; Pamela L Horn-Ross
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

Review 7.  Endometrial cancer disparities: a race-conscious critique of the literature.

Authors:  Kemi M Doll; Cyndy R Snyder; Chandra L Ford
Journal:  Am J Obstet Gynecol       Date:  2017-09-28       Impact factor: 8.661

8.  Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.

Authors:  Marcus E Randall; Virginia Filiaci; D Scott McMeekin; Vivian von Gruenigen; Helen Huang; Catheryn M Yashar; Robert S Mannel; Jae-Weon Kim; Ritu Salani; Paul A DiSilvestro; James J Burke; Thomas Rutherford; Nick M Spirtos; Keith Terada; Penny R Anderson; Wendy R Brewster; William Small; Carol A Aghajanian; David S Miller
Journal:  J Clin Oncol       Date:  2019-04-17       Impact factor: 50.717

9.  Uterine Cancer Incidence and Mortality - United States, 1999-2016.

Authors:  S Jane Henley; Jacqueline W Miller; Nicole F Dowling; Vicki B Benard; Lisa C Richardson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-12-07       Impact factor: 17.586

10.  Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer.

Authors:  Mikko Loukovaara; Annukka Pasanen; Ralf Bützow
Journal:  Cancer Med       Date:  2021-01-15       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.